- Investing Ideas
- Australian Pharmaceuticals & Biotech High Insider Buying
Australian Pharmaceuticals & Biotech High Insider Buying
Results
16
Stocks with high levels of insider buying the past 3 months and good analyst coverage.
16 companies
CSL
Market Cap: AU$75.6b
Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$157.82
7D
14.1%
1Y
-30.0%
Telix Pharmaceuticals
Market Cap: AU$5.7b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
TLX
AU$16.76
7D
-1.1%
1Y
-4.4%
Racura Oncology
Market Cap: AU$414.6m
Operates as a Phase 3 clinical biopharmaceutical company for cancer care.
RAC
AU$2.12
7D
1.0%
1Y
70.3%
Starpharma Holdings
Market Cap: AU$341.1m
A biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally.
SPL
AU$0.71
7D
-2.7%
1Y
450.0%
Nyrada
Market Cap: AU$177.8m
A pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases.
NYR
AU$0.72
7D
-10.0%
1Y
152.6%
Arovella Therapeutics
Market Cap: AU$77.4m
A biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally.
ALA
AU$0.064
7D
3.2%
1Y
-28.9%
Neurizon Therapeutics
Market Cap: AU$45.0m
A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases.
NUZ
AU$0.058
7D
-15.3%
1Y
-62.6%
Patrys
Market Cap: AU$21.3m
Develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases.
PAB
AU$0.032
7D
-8.6%
1Y
113.3%
Peak Processing
Market Cap: AU$19.9m
Manufactures, distributes, and sells recreational cannabis products in Canada and the United States.
PKP
AU$0.015
7D
0%
1Y
-34.8%
Memphasys
Market Cap: AU$18.5m
Develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia.
MEM
AU$0.006
7D
0%
1Y
50.0%
Ceryvyn Therapeutics
Market Cap: AU$15.0m
A clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States.
CYV
AU$0.011
7D
-8.3%
1Y
n/a
Cambium Bio
Market Cap: AU$11.8m
A clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications.
CMB
AU$0.40
7D
-2.4%
1Y
8.1%
Epsilon Healthcare
Market Cap: AU$8.6m
Engages in the healthcare business in Australia.
EPN
AU$0.022
7D
-8.3%
1Y
n/a
Firebrick Pharma
Market Cap: AU$8.0m
Engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally.
FRE
AU$0.028
7D
-22.2%
1Y
-64.1%
Nexalis Therapeutics
Market Cap: AU$2.8m
A biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia.
NX1
AU$0.011
7D
0%
1Y
-70.3%
Cynata Therapeutics
Market Cap: AU$2.7m
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
CYP
AU$0.011
7D
-8.3%
1Y
-94.2%